Todas las noticias

High order volume / Slower-than-expected normalization of supply chains / 2026: growth trajectory confirmed

The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Thursday 2 April 2026 at 10.00 am at the company’s registered office, 7 allée Moulin Berger in Ecully (69).

Le groupe Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a organisé jeudi 19 mars un webinaire au cours duquel, Stéphane Le Roux, PDG de Spineway, et Erwan Martin, Directeur financier, ont présenté les résultats annuels 2025 et les perspectives du Groupe.

• Revenue up 4% • Improved results • Stronger growth potential

In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders deferred from the first half of the year. With revenue of €3.8 million, up 34% compared with Q4 2024 (€2.8 million), Spineway recorded a particularly dynamic fourth quarter.

Spineway participará en el Congreso de la Sociedad Francesa de Cirugía de la Columna Vertebral (SFCR) 2026, que se celebrará del 11 al 13 de junio en el Palais du Pharo de Marsella.

Spineway participará en el congreso EUROSPINE 2026, que se celebrará del 7 al 9 de octubre de 2026 en Gotemburgo, Suecia.

Spineway, a specialist in innovative implants for the treatment of spine disorders, announces the commercial launch of its VEOS and Twin Peaks ranges in Colombia.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that it has conducted several training sessions for surgeons in Europe and Asia, confirming its commitment to helping practitioners master its innovative solutions.